Lung Cancer News

The addition of amivantamab-vmjw to chemotherapy extended PFS among a subset of patients with non-small cell lung cancer, according to the agent’s manufacturer.

Cancer clinical trial participation appeared lower among Black and Latinx patients compared with white patients with various cancer types, according to study results published in JAMA Network Open.

Wastage from dose reduction or discontinuation of the most common oral anticancer drugs costs a mean of $4,290 per patient, results of a retrospective study showed.

Age, sex, BMI, smoking history, nodule size and nodule location — notable factors linked to lung cancer — were also related to this diagnosis in adults with incidentally detected lung nodules, according to study results published in CHEST.

Healio spoke with Howard (Jack) West, MD, associate clinical professor of medical oncology at City of Hope Comprehensive Cancer Center, about results from the ADAURA trial presented at ASCO Annual Meeting.

Healio spoke with Charu Aggarwal, MD, MPH, about data from the Keynote-789 trial presented at this year’s ASCO Annual Meeting.

Healio spoke with Charu Aggarwal, MD, MPH, about results from the Keynote-671 trial presented at this year’s ASCO Annual Meeting.

GO2 for Lung Cancer praised lawmakers in the House and Senate for introducing a bipartisan bill that would increase research focus on the impact of lung cancer among women.

Women receiving cancer treatment in clinical trials exhibited higher risk for severe symptomatic and hematologic adverse events than their male counterparts, according to a study.

Chemoimmunotherapy extended PFS compared with chemotherapy for patients with extensive-stage small cell lung cancer and ECOG performance status of 2 or 3, according to retrospective study results.